{
    "id": 16577,
    "fullName": "KRAS act mut",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "KRAS act mut indicates that the variant results in activation of KRAS downstream signaling. The mechanism causing the activation can include either loss of GTP hydrolysis activity (loss of function) or increased nucleotide exchange rate (gain of function).",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 3845,
        "geneSymbol": "KRAS",
        "terms": [
            "KRAS",
            "'C-K-RAS",
            "C-K-RAS",
            "c-Ki-ras",
            "c-Ki-ras2",
            "CFC2",
            "K-Ras",
            "K-Ras 2",
            "K-RAS2A",
            "K-RAS2B",
            "K-RAS4A",
            "K-RAS4B",
            "KI-RAS",
            "KRAS1",
            "KRAS2",
            "NS",
            "NS3",
            "OES",
            "RALD",
            "RASK2"
        ]
    },
    "variant": "act mut",
    "createDate": "01/15/2016",
    "updateDate": "10/01/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20742,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, activation KRAS mutations were identified in 4 of 100 patients with non-small cell lung cancer at treatment discontinuation of Tagrisso (osimertinib) (PMID: 31839416).",
            "molecularProfile": {
                "id": 16855,
                "profileName": "KRAS act mut"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18023,
                    "pubMedId": 31839416,
                    "title": "Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31839416"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 16855,
            "profileName": "KRAS act mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26404,
            "profileName": "KRAS act mut NF1 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}